Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 9, 2016The Lancet HaematologyOpen Access

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

AFAndrés J.M. FerreriKCKate CwynarskiEPElisa Jacobsen Pulczynski

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ferreri et al. (2016) studied this question.

synapsesocial.com/papers/6a72a755fe4101aa97e0e6bchttps://doi.org/10.1016/s2352-3026(16)00036-3
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology2015 · 424 citations
  2. 2How I treat primary CNS lymphoma2011 · 187 citations
  3. 3Rituximab monotherapy for patients with recurrent primary CNS lymphoma2011 · 198 citations
  4. 4Combined Immunochemotherapy With Reduced Whole-Brain Radiotherapy for Newly Diagnosed Primary CNS Lymphoma2007 · 408 citations
  5. 5Complement Activation and Intraventricular Rituximab Distribution in Recurrent Central Nervous System Lymphoma2013 · 47 citations